231 related articles for article (PubMed ID: 8103046)
1. Mechanism of the enhanced intrinsic activity of single-chain urokinase-type plasminogen activator during ongoing fibrinolysis.
Fleury V; Lijnen HR; Anglés-Cano E
J Biol Chem; 1993 Sep; 268(25):18554-9. PubMed ID: 8103046
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activation with single-chain urokinase-type plasminogen activator (scu-PA). Studies with active site mutagenized plasminogen (Ser740----Ala) and plasmin-resistant scu-PA (Lys158----Glu).
Lijnen HR; Van Hoef B; Nelles L; Collen D
J Biol Chem; 1990 Mar; 265(9):5232-6. PubMed ID: 1969415
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Aug; 262(22):10855-62. PubMed ID: 2956260
[TBL] [Abstract][Full Text] [Related]
4. The mechanism of plasminogen activation and fibrin dissolution by single chain urokinase-type plasminogen activator in a plasma milieu in vitro.
Lijnen HR; Van Hoef B; De Cock F; Collen D
Blood; 1989 May; 73(7):1864-72. PubMed ID: 2713507
[TBL] [Abstract][Full Text] [Related]
5. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158.
Nelles L; Lijnen HR; Collen D; Holmes WE
J Biol Chem; 1987 Apr; 262(12):5682-9. PubMed ID: 3106341
[TBL] [Abstract][Full Text] [Related]
6. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect.
Pannell R; Gurewich V
Blood; 1986 May; 67(5):1215-23. PubMed ID: 3083889
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional characterization of mutants of recombinant single-chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160.
Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
Eur J Biochem; 1988 Nov; 177(3):575-82. PubMed ID: 2973984
[TBL] [Abstract][Full Text] [Related]
8. Differential inhibition of soluble and cell surface receptor-bound single-chain urokinase by plasminogen activator inhibitor type 2. A potential regulatory mechanism.
Schwartz BS
J Biol Chem; 1994 Mar; 269(11):8319-23. PubMed ID: 7907591
[TBL] [Abstract][Full Text] [Related]
9. Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
Barnathan ES; Kuo A; Rosenfeld L; Karikó K; Leski M; Robbiati F; Nolli ML; Henkin J; Cines DB
J Biol Chem; 1990 Feb; 265(5):2865-72. PubMed ID: 2154462
[TBL] [Abstract][Full Text] [Related]
10. Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator.
Li XK; Lijnen HR; Nelles L; Hu MH; Collen D
Biochim Biophys Acta; 1992 Sep; 1159(1):37-43. PubMed ID: 1390910
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
J Biol Chem; 1988 Dec; 263(35):19083-91. PubMed ID: 3143723
[TBL] [Abstract][Full Text] [Related]
12. Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator.
Wolf BB; Vasudevan J; Henkin J; Gonias SL
J Biol Chem; 1993 Aug; 268(22):16327-31. PubMed ID: 8393859
[TBL] [Abstract][Full Text] [Related]
13. Comparative kinetic analysis of the activation of human plasminogen by natural and recombinant single-chain urokinase-type plasminogen activator.
Lijnen HR; Van Hoef B; Collen D
Biochim Biophys Acta; 1986 Dec; 884(3):402-8. PubMed ID: 3778931
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
Jiao J; Yu M; Ru B
Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
[TBL] [Abstract][Full Text] [Related]
15. Activation with plasmin of tow-chain urokinase-type plasminogen activator derived from single-chain urokinase-type plasminogen activator by treatment with thrombin.
Lijnen HR; Van Hoef B; Collen D
Eur J Biochem; 1987 Dec; 169(2):359-64. PubMed ID: 2961562
[TBL] [Abstract][Full Text] [Related]
16. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
Lijnen HR; Dewerchin M; De Cock F; Collen D
Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
[TBL] [Abstract][Full Text] [Related]
17. Differences between neonates and adults in the urokinase-plasminogen activator (u-PA) pathway of the fibrinolytic system.
Ries M; Zenker M; Gaffney PJ
Thromb Res; 2000 Nov; 100(4):341-51. PubMed ID: 11113278
[TBL] [Abstract][Full Text] [Related]
18. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator.
Gheysen D; Lijnen HR; Piérard L; de Foresta F; Demarsin E; Jacobs P; De Wilde M; Bollen A; Collen D
J Biol Chem; 1987 Aug; 262(24):11779-84. PubMed ID: 3114253
[TBL] [Abstract][Full Text] [Related]
20. The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells.
Braat EA; Collen A; Jie AF; Grimbergen JM; Rijken DC
Biochim Biophys Acta; 2000 Sep; 1497(3):351-8. PubMed ID: 10996659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
